➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Colorcon
Medtronic
Baxter
Harvard Business School

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XOPENEX HFA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Xopenex Hfa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00124176 ↗ Continuous Levalbuterol for Treatment of Status Asthmaticus in Children Completed Sunovion Phase 4 2004-04-01 This study will use a randomized, double-blind, controlled trial design in order to assess the safety and efficacy of levalbuterol (LEV) compared to racemic albuterol (RAC) when delivered continuously in a high-dose regimen for children with severe exacerbations of asthma. Primary hypothesis - Children with severe asthma receiving continuous levalbuterol will have a shorter duration of continuous therapy as compared to racemic albuterol. Secondary hypotheses - Children receiving continuous levalbuterol will have improved lung function measured by forced expiratory volume at 1 second (FEV1) as compared to racemic albuterol. - Children receiving continuous levalbuterol will have improved clinical asthma score as compared to racemic albuterol.
NCT00124176 ↗ Continuous Levalbuterol for Treatment of Status Asthmaticus in Children Completed Children's Hospital of Philadelphia Phase 4 2004-04-01 This study will use a randomized, double-blind, controlled trial design in order to assess the safety and efficacy of levalbuterol (LEV) compared to racemic albuterol (RAC) when delivered continuously in a high-dose regimen for children with severe exacerbations of asthma. Primary hypothesis - Children with severe asthma receiving continuous levalbuterol will have a shorter duration of continuous therapy as compared to racemic albuterol. Secondary hypotheses - Children receiving continuous levalbuterol will have improved lung function measured by forced expiratory volume at 1 second (FEV1) as compared to racemic albuterol. - Children receiving continuous levalbuterol will have improved clinical asthma score as compared to racemic albuterol.
NCT00500578 ↗ Intermittent Use of Aerosolized Ribavirin for Treatment of RSV Completed ICN Pharmaceuticals Phase 4 2003-02-01 Primary Objectives: 1. To determine whether aerosolized ribavirin is effective when given at an intermittent dose over 3 hours every 8 hours for therapy of RSV upper respiratory tract infection (URI) and whether it can prevent progression to pneumonia. 2. To determine the effect of this regimen on persistence of viral shedding.
NCT00500578 ↗ Intermittent Use of Aerosolized Ribavirin for Treatment of RSV Completed M.D. Anderson Cancer Center Phase 4 2003-02-01 Primary Objectives: 1. To determine whether aerosolized ribavirin is effective when given at an intermittent dose over 3 hours every 8 hours for therapy of RSV upper respiratory tract infection (URI) and whether it can prevent progression to pneumonia. 2. To determine the effect of this regimen on persistence of viral shedding.
NCT00583947 ↗ A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects Completed Sunovion Phase 2 2008-01-01 To determine the safety and tolerability of Arformoterol Tartrate in children with asthma
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Xopenex Hfa

Condition Name

Condition Name for Xopenex Hfa
Intervention Trials
Asthma 3
Shock 1
Sepsis 1
Hematological Malignancies 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Xopenex Hfa
Intervention Trials
Asthma 2
Neoplasms 1
Status Asthmaticus 1
Respiratory Tract Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Xopenex Hfa

Trials by Country

Trials by Country for Xopenex Hfa
Location Trials
United States 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Xopenex Hfa
Location Trials
Texas 2
Pennsylvania 2
Michigan 2
Oklahoma 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Xopenex Hfa

Clinical Trial Phase

Clinical Trial Phase for Xopenex Hfa
Clinical Trial Phase Trials
Phase 4 5
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Xopenex Hfa
Clinical Trial Phase Trials
Completed 5
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Xopenex Hfa

Sponsor Name

Sponsor Name for Xopenex Hfa
Sponsor Trials
Sunovion 3
Children's Hospital of Philadelphia 1
Fahim Khorfan, MD 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Xopenex Hfa
Sponsor Trials
Other 6
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Express Scripts
Boehringer Ingelheim
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.